248 related articles for article (PubMed ID: 7729473)
1. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro.
Canfield CJ; Pudney M; Gutteridge WE
Exp Parasitol; 1995 May; 80(3):373-81. PubMed ID: 7729473
[TBL] [Abstract][Full Text] [Related]
2. Plasmodium falciparum: interaction of shikimate analogues with antimalarial drugs.
McRobert L; Jiang S; Stead A; McConkey GA
Exp Parasitol; 2005 Nov; 111(3):178-81. PubMed ID: 16140296
[TBL] [Abstract][Full Text] [Related]
3. [Mechanism of action of antimalarials. Value of combined atovaquone/proguanil].
Touze JE; Fourcade L; Pradines B; Hovette P; Paule P; Heno P
Med Trop (Mars); 2002; 62(3):219-24. PubMed ID: 12244914
[TBL] [Abstract][Full Text] [Related]
4. Multiple synergistic interactions between atovaquone and antifolates against Plasmodium falciparum in vitro: a rational basis for combination therapy.
Nduati EW; Kamau EM
Acta Trop; 2006 Mar; 97(3):357-63. PubMed ID: 16457769
[TBL] [Abstract][Full Text] [Related]
5. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration.
Edstein MD; Kotecka BM; Anderson KL; Pombo DJ; Kyle DE; Rieckmann KH; Good MF
Antimicrob Agents Chemother; 2005 Oct; 49(10):4421-2. PubMed ID: 16189139
[No Abstract] [Full Text] [Related]
6. Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum.
Fivelman QL; Adagu IS; Warhurst DC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4097-102. PubMed ID: 15504827
[TBL] [Abstract][Full Text] [Related]
7. In vitro recrudescence of Plasmodium falciparum parasites suppressed to dormant state by atovaquone alone and in combination with proguanil.
Thapar MM; Gil JP; Björkman A
Trans R Soc Trop Med Hyg; 2005 Jan; 99(1):62-70. PubMed ID: 15550263
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic interaction between atovaquone and other antimalarial compounds against Plasmodium falciparum in vitro.
Lütgendorf C; Rojanawatsirivet C; Wernsdorfer G; Sirichaisinthop J; Kollaritsch H; Wernsdorfer WH
Wien Klin Wochenschr; 2006; 118(19-20 Suppl 3):70-6. PubMed ID: 17131244
[TBL] [Abstract][Full Text] [Related]
9. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers.
Musset L; Pradines B; Parzy D; Durand R; Bigot P; Le Bras J
J Antimicrob Chemother; 2006 Jan; 57(1):110-5. PubMed ID: 16319183
[TBL] [Abstract][Full Text] [Related]
10. Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo.
Vivas L; Rattray L; Stewart LB; Robinson BL; Fugmann B; Haynes RK; Peters W; Croft SL
J Antimicrob Chemother; 2007 Apr; 59(4):658-65. PubMed ID: 17337512
[TBL] [Abstract][Full Text] [Related]
11. Persistence of atovaquone in human sera following treatment: inhibition of Plasmodium falciparum development in vivo and in vitro.
Butcher GA; Sinden RE
Am J Trop Med Hyg; 2003 Jan; 68(1):111-4. PubMed ID: 12556158
[TBL] [Abstract][Full Text] [Related]
12. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe.
Wichmann O; Muehlberger N; Jelinek T; Alifrangis M; Peyerl-Hoffmann G; Muhlen M; Grobusch MP; Gascon J; Matteelli A; Laferl H; Bisoffi Z; Ehrhardt S; Cuadros J; Hatz C; Gjorup I; McWhinney P; Beran J; da Cunha S; Schulze M; Kollaritsch H; Kern P; Fry G; Richter J;
J Infect Dis; 2004 Nov; 190(9):1541-6. PubMed ID: 15478057
[TBL] [Abstract][Full Text] [Related]
13. Plasmodium falciparum outwits Malarone, protector of travellers.
Crabb C
Bull World Health Organ; 2003; 81(5):382-3. PubMed ID: 12856058
[No Abstract] [Full Text] [Related]
14. Effects of hydroxypyridinone iron chelators in combination with antimalarial drugs on the in vitro growth of Plasmodium falciparum.
Pattanapanyasat K; Kotipun K; Yongvanitchit K; Hider RC; Kyle DE; Heppner DG; Walsh DS
Southeast Asian J Trop Med Public Health; 2001 Mar; 32(1):64-9. PubMed ID: 11485097
[TBL] [Abstract][Full Text] [Related]
15. [What is the value of the combination atovaquone-proguanil for the clinician?].
Delmont J
Med Trop (Mars); 2002; 62(3):232-6. PubMed ID: 12244917
[TBL] [Abstract][Full Text] [Related]
16. Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate.
Gupta RK; Van Vugt M; Paiphun L; Slight T; Looareesuwan S; White NJ; Nosten F
Am J Trop Med Hyg; 2005 Aug; 73(2):267-8. PubMed ID: 16103586
[TBL] [Abstract][Full Text] [Related]
17. Molecular epidemiology of malaria in Cameroon. XVII. Baseline monitoring of atovaquone-resistant Plasmodium falciparum by in vitro drug assays and cytochrome b gene sequence analysis.
Basco LK
Am J Trop Med Hyg; 2003 Aug; 69(2):179-83. PubMed ID: 14506774
[TBL] [Abstract][Full Text] [Related]
18. Atovaquone + proguanil: new preparation. Second-line antimalarial combination.
Prescrire Int; 2002 Oct; 11(61):131-6. PubMed ID: 12378742
[TBL] [Abstract][Full Text] [Related]
19. [Clinical studies using the combination atovaquone-proguanil as malaria prophylaxis in non-immune adult and child travelers].
Camus D; Dutoit E; Masson V; Inglebert P; Delhaes L
Med Trop (Mars); 2002; 62(3):225-8. PubMed ID: 12244915
[TBL] [Abstract][Full Text] [Related]
20. Atovaquone/proguanil for the prophylaxis and treatment of malaria.
Patel SN; Kain KC
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):849-61. PubMed ID: 16307498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
